Diaceutics Unveils Innovative Pathology Engagement Service
Diaceutics PLC (AIM: LON: DXRX), a prominent provider of technology and solutions tailored for the pharmaceutical and biotech sectors, has recently introduced its new Pathology Engagement Liaisons (PEL) service. This innovative offering is part of an effort to bridge crucial connections between pharmaceutical companies and laboratories.
Contract Worth $1.8 Million with Global Pharmaceutical Leader
In a significant move, the company secured a contract with a leading global pharmaceutical firm, potentially valued at up to $1.8 million over the next year. This partnership is aimed at enhancing laboratory pathologists' education and engagement, particularly in pancreatic cancer testing.
Enhancing Patient Care through Education
The PEL service's primary focus is to supplement Diaceutics' existing PMx commercialization solutions. By improving the engagement of laboratory pathologists, the initiative is expected to create a more direct line of communication between pharmaceutical companies and laboratories, ultimately benefiting patients who rely on timely and accurate biomarker testing.
Leveraging the DXRX Platform for Better Outcomes
Utilizing the established DXRX platform and its expansive laboratory network, Diaceutics aims to advance the understanding of biomarker testing. Through this initiative, the company is poised to significantly boost the adoption of crucial biomarker tests, improving diagnostic education globally.
Leadership Insights on the Impact of PEL
Susanne Munksted, the Chief Precision Medicine Officer at Diaceutics, highlighted the significant impact this service could have on patient outcomes. By collaborating closely with pharmaceutical clients, the PEL service is set to introduce new therapeutic approaches to patients requiring advanced treatment options.
Extending the Reach of Biomarker Education and Testing
The contract will see the PEL service implemented across numerous laboratories in the DXRX network throughout the United States, focusing on enhancing the education of pathologists specializing in immunohistochemistry testing for pancreatic cancer. This initiative is crucial for improving the awareness and understanding of biomarker testing, supporting the introduction of recently approved therapies.
Benefits of Integrating PEL with Existing Solutions
Though the PEL service stands alone, it is also designed to harmonize with Diaceutics' existing PMx commercialization solutions. This integration is likely to further optimize laboratory testing processes and bolster patient recruitment for essential therapies. The addition of PEL will allow Diaceutics to enhance its relevance to therapy brands and is expected to increase revenue per brand significantly.
Conclusion
Diaceutics' launch of the PEL service marks a pivotal step in improving patient care through enhanced pathology education and engagement in the biomarker space. By effectively connecting the pharmaceutical industry with laboratory environments, this initiative aims to foster a more informed and proactive approach to cancer treatment.
Frequently Asked Questions
What is the Pathology Engagement Liaisons (PEL) service?
The PEL service is an initiative by Diaceutics aimed at enhancing the education and engagement of laboratory pathologists in the context of biomarker testing, especially for pancreatic cancer.
How much is the contract Diaceutics secured?
The secured contract with a global pharmaceutical company is potentially worth up to $1.8 million over the next 12 months.
What is the duration of the contract mentioned?
The contract is expected to run through the end of 2025, focusing on the deployment of the PEL service across relevant laboratories.
How does the PEL service impact patient outcomes?
The PEL service aims to improve patient outcomes by enhancing laboratory testing practices, increasing biomarker education, and facilitating better therapy options for patients in need.
Can the PEL service be integrated with existing Diaceutics offerings?
Yes, the PEL service can be integrated with Diaceutics' PMx commercialization solutions, optimizing laboratory testing and enhancing patient recruitment for therapies.
